Detalhe da pesquisa
1.
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Cancer
; 130(11): 1930-1939, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340349
2.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Oncologist
; 29(3): 235-243, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37812679
3.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394384
4.
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
BJU Int
; 131(4): 452-460, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087070
5.
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Future Oncol
; 18(1): 35-45, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636627
6.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
Eur Urol
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644146
7.
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Eur J Cancer
; 192: 113258, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37660438
8.
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study.
J Nucl Med
; 64(4): 574-578, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36302656
9.
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.
EClinicalMedicine
; 60: 101993, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37251627
10.
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study).
J Nucl Med
; 64(12): 1925-1931, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827838
11.
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
J Clin Oncol
; 41(20): 3595-3607, 2023 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795843
12.
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Eur Urol
; 83(3): 212-221, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36089529
13.
177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience.
J Nucl Med
; 63(3): 410-414, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34168015
14.
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
Prostate Cancer Prostatic Dis
; 25(2): 306-313, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35190653
15.
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.
Front Med (Lausanne)
; 92022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36619649
16.
Comment on the Safety of Enterococcus faecium SF68.
J Pediatr Gastroenterol Nutr
; 62(1): e12, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26252925
17.
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Target Oncol
; 14(5): 527-539, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31571095
18.
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022].
Eur Urol
; 83(2): e60, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36526492
19.
Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T-cell depletion with T-cell add-back.
Eur J Haematol
; 83(3): 273-5, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19500136